Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes.

Abstract	We investigated the signal transduction pathway of IL-12 and showed that lisofylline (LSF) inhibited the signal transducer and activator of transcription factor-4 (STAT4) activation. Interruption of IL-12-mediated STAT4 activation prevented autoimmune diabetes in NOD mice.
Authors	Zandong Yang, Meng Chen, Lawrence B Fialkow, Justin D Ellett, Runpei Wu, Jerry L Nadler
Journal	Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1005 Pg. 409-11 (Nov 2003) ISSN: 0077-8923 [Print] United States
PMID	14679102 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References	DNA-Binding Proteins Immunosuppressive Agents STAT4 Transcription Factor STAT4 protein, human Trans-Activators Interleukin-12 lisofylline Pentoxifylline
Topics	DNA-Binding Proteins (antagonists & inhibitors, metabolism) Diabetes Mellitus, Type 1 (prevention & control) Humans Immunosuppressive Agents (pharmacology) Interleukin-12 (metabolism) Pentoxifylline (analogs & derivatives, pharmacology) Phosphorylation STAT4 Transcription Factor Signal Transduction Trans-Activators (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!